Share Price:

APNASPENAspen Pharmacare Hldgs961032 (0.33%)

Aspen announces local availability of Lilly’s Mounjaro

Stephen Saad, Aspen Group Chief Executive

Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.

Aspen and SEMDSA highlight the alarming rise of non-communicable diseases on World Diabetes Day

Heinz Schütte, Aspen Pharmacare Regional CEO, Dr Reyna Daya, SEMDSA President & Endocrinologist, and Stavros Nicolau, Aspen Group Senior Executive Strategic Trade

Aspen and SEMDSA earlier today raised awareness around the alarming rise of non-communicable diseases, particularly diabetes, in recognition of World Diabetes Day.

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.